Aclaris Therapeutics Inc (NASDAQ:ACRS) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $21.43 and last traded at $22.27, with a volume of 631400 shares. The stock had previously closed at $23.71.
Several equities research analysts recently issued reports on ACRS shares. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 price objective on shares of Aclaris Therapeutics in a research note on Tuesday, November 7th. Zacks Investment Research raised Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research note on Tuesday, October 10th. ValuEngine downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. JMP Securities reissued an “outperform” rating and issued a $39.00 price objective on shares of Aclaris Therapeutics in a research note on Friday, September 8th. Finally, BidaskClub downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $39.20.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.23. The business had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $2.00 million. analysts predict that Aclaris Therapeutics Inc will post -2.59 earnings per share for the current fiscal year.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
What are top analysts saying about Aclaris Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aclaris Therapeutics Inc and related companies.